**Emergency Medical Care Committee Meeting Minutes** Thursday November 30<sup>th</sup>, 2023 2995 McMillan Ave, Ste 178, San Luis Obispo



Members  ☐ CHAIR Jonathan Stornetta, Public Providers ☐ VICE CHAIR Dr. Brad Knox, <i>Physicians</i>	Ex Officio  Vince Pierucci, EMS Division Director  Dr. Bill Mulkerin, LEMSA Medical Director
<ul> <li>☑ Bob Neumann, Consumers</li> <li>☑ Alexandra Kohler, Consumers</li> <li>☑ Matt Bronson, City Government</li> <li>☑ Chris Javine, Pre-Hospital Transport Providers</li> <li>☑ Michael Talmadge, EMS Field Personnel</li> <li>☑ Dr. Rachel May, Emergency Physicians</li> <li>☑ Jay Wells, Sheriff's Department</li> <li>☑ Julia Fogelson, Hospitals</li> <li>☑ Diane Burkey, MICNs</li> </ul>	Staff  ☐ Rachel Oakley, EMS Coordinator ☐ David Goss, EMS Coordinator ☐ Ryan Rosander, EMS Coordinator ☐ Denise Yi, PHEP Program Manager ☐ Alyssa Vardas, Administrative Assistant Guests – Rob Jenkins, CALFire; Pete Gaviitz, CHP, Doug Weeda
AGENDA ITEM / DISCUSSION	ACTION
CALL TO ORDER	The meeting called to order at 08:35 AM
Introductions	
Public Comment	No comments
Approval of Meeting Minutes –	No quorum
<ul> <li>Staff Report for revisions to policy #343, Field Training Officer (FTO Program: <ul> <li>The EMS Agency felt it was time to update the FTO policy due to increase in call volume and the need to increase the available in FTOs.</li> <li>Policy #343 was brought to the Operations Subcommittee with the recommended revisions implemented to enhance the overall surphie the Field Training Officer program within the county. The Operat Subcommittee recommended it be brought to the Emergency M Care Committee for review.</li> <li>The proposed revisions are as follows:</li> <li>Establishing an FTO I and an FTO II</li> <li>FTO I and FTO II duties and requirements</li> <li>FTO liaison duties</li> <li>Process/requirements for application/reapplication for all FTOs.</li> <li>Continuing requirements for FTO I &amp; II.</li> </ul> </li> </ul>	o an umber of he ccess of tions
Discussion:  M. Talmadge – Those minimum qualifications apply to all FTOs correct?  R. Rosander – FTO liaison is the main point of contact with the EMS Age B. Knox – Is there a reason the score is 80%? Shouldn't it be higher?  R. Rosander – Current is higher, and we can put it higher.  B. Knox – How about 90%?  R. Rosander – not many get 90%.  D. Burkey – How many questions?  R. Oakley – 90, around 40 get randomly selected.  C. Javine – What about Grandfathered FTOs?  R. Rosander - The first two years are catching up to speed and having the test to move into the FTO II spot.  M. Bronson – Is there a fiscal impact to this?	

V. Pierucci – The only fiscal impact is to pay the FTOs. B. Neumann – How many FTOs are we currently running? R. Rosander – Not many. B. Knox – Would training fall into the FTO category? C. Javine – No. V. Pierucci – No. C. Javine – Should we change it to the national standard course? J. Stornetta – Could we utilize track changes in the future?  Motion to approve with changes.  The staff report for the addition of Amiodarone:  • Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse. • Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs. • Amiodarone is ready to be implemented following the recommendation of the EMCC. •  Discussion: M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS. R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
R. Rosander – Not many. B. Knox – Would training fall into the FTO category? C. Javine – No. V, Pierucci – No. C. Javine – Should we change it to the national standard course? J. Stornetta – Could we utilize track changes in the future?  Motion to approve with changes.  The staff report for the addition of Amiodarone:  • Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse. • Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs. • Amiodarone is ready to be implemented following the recommendation of the EMCC. • Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented? B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS. R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
B. Knox – Would training fall into the FTO category? C. Javine – No. V, Pierucci – No. C. Javine – Should we change it to the national standard course? J. Stornetta – Could we utilize track changes in the future?  Motion to approve with changes.  The staff report for the addition of Amiodarone:  • Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse.  • Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.  • Amiodarone is ready to be implemented following the recommendation of the EMCC.  • Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented? B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
C. Javine – No. V, Pierucci – No. C. Javine – Should we change it to the national standard course? J. Stornetta – Could we utilize track changes in the future?  Motion to approve: J. Stornetta, B. Knox Second. All in favor.  The staff report for the addition of Amiodarone:  • Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse.  • Amiodarone was fought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.  • Amiodarone is ready to be implemented following the recommendation of the EMCC.  • Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
V, Pierucci – No. C. Javine – Should we change it to the national standard course? J. Stornetta – Could we utilize track changes in the future?  Motion to approve with changes.  The staff report for the addition of Amiodarone:  • Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse.  • Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.  • Amiodarone is ready to be implemented following the recommendation of the EMCC.  • Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
C. Javine – Should we change it to the national standard course?  J. Stornetta – Could we utilize track changes in the future?  Motion to approve: J. Stornetta, B. Knox Second. All in favor.  The staff report for the addition of Amiodarone:  • Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse.  • Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.  • Amiodarone is ready to be implemented following the recommendation of the EMCC.  • Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
J. Stornetta – Could we utilize track changes in the future?  Motion to approve with changes.  Motion to approve with changes.  The staff report for the addition of Amiodarone:  • Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse.  • Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.  • Amiodarone is ready to be implemented following the recommendation of the EMCC.  • Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
Motion to approve with changes.  The staff report for the addition of Amiodarone:  • Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse.  • Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.  • Amiodarone is ready to be implemented following the recommendation of the EMCC.  • Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
Motion to approve with changes.  The staff report for the addition of Amiodarone:  • Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse.  • Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.  • Amiodarone is ready to be implemented following the recommendation of the EMCC.  • Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
The staff report for the addition of Amiodarone:  • Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse.  • Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.  • Amiodarone is ready to be implemented following the recommendation of the EMCC.  • Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
<ul> <li>Amiodarone was found to be an improvement for out-of-hospital cardiac arrest patients and patients experiencing Ventricular Tachycardia Pulse.</li> <li>Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.</li> <li>Amiodarone is ready to be implemented following the recommendation of the EMCC.</li> <li>Discussion:         <ul> <li>M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?</li> <li>B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.</li> <li>R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.</li> <li>D. Burkey – Are there other counties doing the dual sequential defibrillation and</li> </ul> </li> </ul>
arrest patients and patients experiencing Ventricular Tachycardia Pulse.  Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.  Amiodarone is ready to be implemented following the recommendation of the EMCC.  Biscussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
arrest patients and patients experiencing Ventricular Tachycardia Pulse.  Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.  Amiodarone is ready to be implemented following the recommendation of the EMCC.  Biscussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
<ul> <li>Amiodarone was brought to the Clinical Advisory Subcommittee and the Operations Subcommittee to follow ACLS and Other LEMSAs.</li> <li>Amiodarone is ready to be implemented following the recommendation of the EMCC.</li> <li>Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.</li> <li>R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.</li> <li>D. Burkey – Are there other counties doing the dual sequential defibrillation and</li> </ul>
Operations Subcommittee to follow ACLS and Other LEMSAs.  • Amiodarone is ready to be implemented following the recommendation of the EMCC.  • Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
<ul> <li>Amiodarone is ready to be implemented following the recommendation of the EMCC.</li> <li>Discussion:         M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?         B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.         R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.         D. Burkey – Are there other counties doing the dual sequential defibrillation and     </li> </ul>
the EMCC.  Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
Discussion:  M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
M. Talmadge – Are we still going to be stocking Lidocaine if this is going to be implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
implemented?  B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
B. Knox – Neither Amiodarone nor Lidocaine has been shown to have a clear impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
impact on survival with good neurologic outcomes. Having said that, though, I am in support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
support of this change to maintain consistency with ACLS.  R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
R. May – There is no proof that Amiodarone supports continuous life after discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
discharge, I think it could help and that there are benefits but there are other things out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
out there.  D. Burkey – Are there other counties doing the dual sequential defibrillation and
D. Burkey – Are there other counties doing the dual sequential defibrillation and
vector change defibrillation?
vector change defibrillation?
V. Pierucci – Kern County.
R. May – I want to request that we hold up the Amiodarone change so we can add
language to the cardiac arrest protocol to address these.
B. Knox – I think the consensus is that we don't want to hold up this change for an
entirely different discussion that is best had through standard channels at the
Clinical Advisory Committee and then brought to EMCC.
V. Pierucci – We can move forward with Amiodarone before talking about others
later.
Motion for approval  Motion to Approve: B. Knox, second: C.
Motion for approval.  Motion to Approve: B. Knox, second: C.  Javine.
EMSA Director Report: V. Pierucci
v. Fierucci
EMS Medical Director Report:  B. Mulkerin
I am getting up and running in this new position and please feel free to reach out.
We are still seeing medication shortages.
vve are suit seemy medication shortages.
PHEP Staff Report: D. Yi
Nothing to report.
Announcements:
None
Future Agenda Items: Adjourn at 9:53 AM.
Future Agenda Items: None  Adjourn at 9:53 AM.
None
None Next Regular Meeting
None

